A Toolkit for Developing Palliative Care Programs in the

Warnings and Precautions section) include haemorrhage, PRES, arterial thromboembolic events and cardiac dysfunction. Fatal cases of pneumonia and sepsis have been seen in previous studies of pembrolizumab and are described in the Australian PI for pembrolizumab. ................
................